Very excited to finally open this position:
PhD on microbial genome evolution, with emphasis on studying genome architecture in bacteria and archaea.
https://t.co/TJQBOowzvu
Please RT and share with talented MSc students in bioinformatics, evol biology or related fields :)
Our last Cell Therapy Landscape analysis is out! Thank you to my colleagues at @CancerResearch, our collaborators at @IQVIA_global, and to @NatRevDrugDisc. A few key points from this piece:
CRI scientists report a 36% increase of active cell therapy agents in the global immuno-oncology pipeline in the last year, a deceleration compared to previous years, in a new @NatRevDrugDisc analysis.
https://t.co/VxwuvKCuJS
4- Check our supplementary materials for a complete view on barriers to CAR-T implementation, together with several other informative figures that complete this analysis. (end of ๐งต)
My mentor Ana Maria Cuervo, one of the most talented scientist I have ever met and probably one of the nicest person on earth is being inducted today at @theNASciences. So well deserved! #AMC#CMA#WomenInAutophagy
Which are best? โNK vs T-cellsโdebate at #IO360nyc โฆa really fun and engaging way to present the topic, specially important in a conference that attracts such a range of biotech professionals, from investors to clinicians
Speaking with @CancerResearch's Jill O'Donnell-Tormey. CRI has been doing IO research (both basic and clinical) since the 1950's, really! A great organization to support. https://t.co/LjsaFbQFR4 #IO360NYC
@bradloncar I sympathized with Dr. Nieva very much on what he said. But again, FDA can not take pricing into consideration for regulatory decisionsโฆ.
Happy Women in Science Day to all the female scientists doing amazing work worldwide! Special appreciation to our labโs female scientists who do incredible research each day ๐ฉ๐ปโ๐ฌ #WomenInScience